
|Articles|November 1, 2001
Ciprofloxacin study warns of adverse events
Ciprofloxacin (Cipro), the medicine of choice for treatingcutaneous anthrax as well as other forms of the disease, can cause adversedrug reactions in both the central nervous system and the peripheral nervoussystem, according to studies in The Journal of Pharmacotherapy
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











